Priscilla Soares Filgueiras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Priscilla Soares Filgueiras has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Rafaella Fortini Queiroz Grenfell
Fundacao Oswaldo Cruz (FIOCRUZ), Brazil
5 shared publications - Nathalie Bonatti Franco Almeida
Departamento de Física, Universidade Federal de Minas Gerais, Avenida Presidente Antônio Carlos 6627 Belo Horizonte, Minas Gerais 31270-901, Brazil
3 shared publications Camila Amormino Corsini
Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil
2 shared publications- Camila Amormino Corsini
Instituto René Rachou—Fundação Oswaldo Cruz, Avenida Augusto de Lima 1715, Belo Horizonte, Minas Gerais 30190-002, Brazil
2 shared publications - Maurício Lacerda Nogueira
Department of Pathology, University of Texas Medical Branch, Galveston, USA
2 shared publications - Pedro Augusto Alves
FIOCRUZ
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2026 (1) , 3683298
Long‐Term Immunogenicity, Safety, and Reactogenicity of CoronaVac and Heterologous Booster Vaccines: A Two‐Year Cohort Study in Brazil
This two‐year cohort study evaluated immunogenicity, safety, and reactogenicity in 1675 Brazilian healthcare workers who received CoronaVac as a primary protocol (PP) followed by heterologous boosters. All vaccines were safe, with no serious adverse events. Reactogenicity was highest for Ad26.COV2.S (62.86%) as a second booster, followed by Covishield (58.56%) and Comirnaty (42.62%); CoronaVac PP reactogenicity was 19.58%. Total anti‐S IgG levels remained high throughout, increasing after the first booster. At 9 months post‐PP, Comirnaty‐boosted individuals showed superior responses versus CoronaVac alone, regardless of prior infection. No differences were observed between one or two boosters, age groups, or sex. Initially, previously infected participants had higher anti‐S IgG (6–9 months), but this difference disappeared post‐booster. Neutralizing antibodies against Omicron BA.1 were stronger in previously infected individuals at 6–12 months. The first booster increased neutralization in both groups; the second booster further enhanced responses in infection‐naive individuals and maintained them in previously infected participants, with sustained activity up to 24 months. Participants with prior COVID‐19 showed higher levels of immunological biomarkers early on, but this gap closed after the second booster, which elevated biomarkers in both groups. Cellular response, inferred from biomarker interactions, was generally higher in infection‐naive individuals. These results underscore the importance of heterologous booster regimens in sustaining long‐term humoral and cellular immunity against COVID‐19.
- 1 January 2026
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2026 (1) , 3683298
Open AccessLong‐Term Immunogenicity, Safety, and Reactogenicity of CoronaVac and Heterologous Booster Vaccines: A Two‐Year Cohort Study in Brazil
This two‐year cohort study evaluated immunogenicity, safety, and reactogenicity in 1675 Brazilian healthcare workers who received CoronaVac as a primary protocol (PP) followed by heterologous boosters. All vaccines were safe, with no serious adverse events. Reactogenicity was highest for Ad26.COV2.S (62.86%) as a second booster, followed by Covishield (58.56%) and Comirnaty (42.62%); CoronaVac PP reactogenicity was 19.58%. Total anti‐S IgG levels remained high throughout, increasing after the first booster. At 9 months post‐PP, Comirnaty‐boosted individuals showed superior responses versus CoronaVac alone, regardless of prior infection. No differences were observed between one or two boosters, age groups, or sex. Initially, previously infected participants had higher anti‐S IgG (6–9 months), but this difference disappeared post‐booster. Neutralizing antibodies against Omicron BA.1 were stronger in previously infected individuals at 6–12 months. The first booster increased neutralization in both groups; the second booster further enhanced responses in infection‐naive individuals and maintained them in previously infected participants, with sustained activity up to 24 months. Participants with prior COVID‐19 showed higher levels of immunological biomarkers early on, but this gap closed after the second booster, which elevated biomarkers in both groups. Cellular response, inferred from biomarker interactions, was generally higher in infection‐naive individuals. These results underscore the importance of heterologous booster regimens in sustaining long‐term humoral and cellular immunity against COVID‐19.
- Open Access
- 2 August 2024
- Published by IOP Publishing in Nanotechnology
- Vol. 35 (42) , 425503
Ultrafast and highly sensitive detection of SARS-CoV-2 spike protein by field-effect transistor graphene-based biosensors
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etiological agent for the coronavirus disease 2019 (COVID-19), has resulted in over 775 million global infections. Early diagnosis remains pivotal for effective epidemiological surveillance despite the availability of vaccines. Antigen-based assays are advantageous for early COVID-19 detection due to their simplicity, cost-effectiveness, and suitability for point-of-care testing (PoCT). This study introduces a graphene field-effect transistor-based biosensor designed for high sensitivity and rapid response to the SARS-CoV-2 spike protein. By functionalizing graphene with monoclonal antibodies and applying short-duration gate voltage pulses, we achieve selective detection of the viral spike protein in human serum within 100 µs and at concentrations as low as 1 fg ml−1, equivalent to 8 antigen molecules per µl of blood. Furthermore, the biosensor estimates spike protein concentrations in serum from COVID-19 patients. Our platform demonstrates potential for next-generation PoCT antigen assays, promising fast and sensitive diagnostics for COVID-19 and other infectious diseases.
- 2 August 2024
- Published by IOP Publishing in Nanotechnology
- Vol. 35 (42) , 425503
Open AccessUltrafast and highly sensitive detection of SARS-CoV-2 spike protein by field-effect transistor graphene-based biosensors
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etiological agent for the coronavirus disease 2019 (COVID-19), has resulted in over 775 million global infections. Early diagnosis remains pivotal for effective epidemiological surveillance despite the availability of vaccines. Antigen-based assays are advantageous for early COVID-19 detection due to their simplicity, cost-effectiveness, and suitability for point-of-care testing (PoCT). This study introduces a graphene field-effect transistor-based biosensor designed for high sensitivity and rapid response to the SARS-CoV-2 spike protein. By functionalizing graphene with monoclonal antibodies and applying short-duration gate voltage pulses, we achieve selective detection of the viral spike protein in human serum within 100 µs and at concentrations as low as 1 fg ml−1, equivalent to 8 antigen molecules per µl of blood. Furthermore, the biosensor estimates spike protein concentrations in serum from COVID-19 patients. Our platform demonstrates potential for next-generation PoCT antigen assays, promising fast and sensitive diagnostics for COVID-19 and other infectious diseases.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 56, e0167-2022
Rapid antigen test as a tool for the identification of SARS-CoV-2 infection and its potential as a self-testing device
SARS-CoV-2 virus originated in Wuhan (China) in December (2019) and quickly spread worldwide. Antigen tests are rapid diagnostic tests (RDT) that produce results in 15-30 min and are an important tool for the scale-up of COVID-19 testing. COVID-19 diagnostic tests are authorized for self-testing at home in some countries, including Brazil. Widespread COVID-19 diagnostic testing is required to guide public health policies and control the speed of transmission and economic recovery.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 56, e0167-2022
Open AccessRapid antigen test as a tool for the identification of SARS-CoV-2 infection and its potential as a self-testing device
SARS-CoV-2 virus originated in Wuhan (China) in December (2019) and quickly spread worldwide. Antigen tests are rapid diagnostic tests (RDT) that produce results in 15-30 min and are an important tool for the scale-up of COVID-19 testing. COVID-19 diagnostic tests are authorized for self-testing at home in some countries, including Brazil. Widespread COVID-19 diagnostic testing is required to guide public health policies and control the speed of transmission and economic recovery.
- Open Access
- 29 June 2022
- Published by Springer Nature in Communications Medicine
- Vol. 2 (1) , 1-4
Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant
Background: The emergence of the new SARS-CoV-2 Omicron variant, which is known to have a large number of mutations when compared to other variants, brought to light the concern about vaccine escape, especially from the neutralization by antibodies induced by vaccination. Methods: Based on viral microneutralization assays, we evaluated in 90 individuals the impact on antibody neutralization induction, against Omicron variant, by a booster dose of BNT162b2 mRNA vaccine after the CoronaVac primary vaccination scheme. Results: Here we show that the percentage of seroconverted individuals 30 and 60 days after CoronaVac scheme was 16.6% and 10%, respectively. After booster dose administration, the seroconvertion rate increased to 76.6%. The neutralization mean titer against Omicron in the CoronaVac protocol decreased over time, but after the booster dose, the mean titer increased 43.1 times. Conclusions: These results indicate a positive impact of this vaccine combination in the serological immune response against SARS-CoV-2 Omicron variant.
- 29 June 2022
- Published by Springer Nature in Communications Medicine
- Vol. 2 (1) , 1-4
Open AccessBooster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant
Background: The emergence of the new SARS-CoV-2 Omicron variant, which is known to have a large number of mutations when compared to other variants, brought to light the concern about vaccine escape, especially from the neutralization by antibodies induced by vaccination. Methods: Based on viral microneutralization assays, we evaluated in 90 individuals the impact on antibody neutralization induction, against Omicron variant, by a booster dose of BNT162b2 mRNA vaccine after the CoronaVac primary vaccination scheme. Results: Here we show that the percentage of seroconverted individuals 30 and 60 days after CoronaVac scheme was 16.6% and 10%, respectively. After booster dose administration, the seroconvertion rate increased to 76.6%. The neutralization mean titer against Omicron in the CoronaVac protocol decreased over time, but after the booster dose, the mean titer increased 43.1 times. Conclusions: These results indicate a positive impact of this vaccine combination in the serological immune response against SARS-CoV-2 Omicron variant.
- Open Access
- 1 January 2021
- Published by Bio-Manguinhos Fiocruz
- p. 21
Production of a monoclonal antibody against SARS-CoV-2 and determination of viral neutralization capacity
- 1 January 2021
- Published by Bio-Manguinhos Fiocruz
- p. 21
Open AccessProduction of a monoclonal antibody against SARS-CoV-2 and determination of viral neutralization capacity